ClinicalTrials.gg
Status unknownNCT00043576Updated Mar 12, 2009

ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere

A Phase 2/3 interventional study of calcitriol and docetaxel in Prostate Cancer, sponsored by Novacea. Status unknown at 62 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-03-12.

Sponsored by Novacea · Phase 2/3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2005), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 15 studies testing calcitriol in Prostatic Neoplasms — none open to participants now, none under way, none of them phase 3. Calcitriol · Prostatic Neoplasms.

Enrollment
2nd of 14
250 · median 21
Started
2002
with 2 others
Phase 2/3
Only one
of the 15
Registered
5th of 15
by date
Lead sponsor
3 of 15
Novacea

Among the 15 studies testing calcitriol in Prostatic Neoplasms, this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2002, is the only one in phase 2/3, and was the 5th registered.

Prostatic Neoplasms

7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

None of the 15 studies testing calcitriol in Prostatic Neoplasms is open now. The open studies under Prostatic Neoplasms, anywhere →

About calcitriol

Calcitriol: first FDA approval 1978 (ROCALTROL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing calcitriol in Prostatic Neoplasms as a file.
02

Study summary

The purposes of this study are to determine if DN-101 plus Taxotere lowers PSA levels, delays or limits disease progression and is safe with minimal side effects.

Read the detailed description

DN-101 is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA). It is a newly formulated pill that contains high amounts of calcitriol, a naturally occurring hormone and the biologically active form of vitamin D. Administration of DN-101 results in much higher blood levels of calcitriol than the body can produce from dietary vitamin D or vitamin D supplements. These higher levels of calcitriol are associated with anti-cancer effects in laboratory models of human cancer. Laboratory models also indicate that calcitriol has synergy with many commonly used chemotherapeutic agents used to treat cancer.

Calcitriol, at very low doses, is currently approved for use in patients with chronic kidney failure. DN-101 was specifically designed for cancer and contains 30 times the amount of calcitriol found in the calcitriol pill commercially available today. In order to take an amount of calcitriol equivalent to 1 DN-101 pill, cancer patients would need to swallow 30 pills of the approved, low dose formulation. DN-101 represents a breakthrough in the use of calcitriol in the clinic, because it contains high concentrations of calcitriol and makes it more feasible for patients to stay on regimen.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • Androgen Independent Prostate Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

  • Three rising PSA measurements OR a new lesion
  • Adequate liver and kidney function
  • Ongoing hormonal therapy
  • No hospitalization for angina, heart attack or congestive heart failure within the last 12 months
  • No kidney stones in the last 5 years
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
250 participants

Interventions

06

Study locations

62 sites
  • Montgomery Cancer Center
    Montgomery, Alabama 36106, United States
  • Arizona Cancer Center- Scottsdale
    Scottsdale, Arizona 85258, United States
  • Arizona Cancer Center/Southern Arizona VA HCS
    Tucson, Arizona 85723, United States
  • Arizona Cancer Center- Tucson
    Tucson, Arizona 85724, United States
  • University of Arkansas for Medical Sciences / Central AR VA
    Little Rock, Arkansas 72205, United States
  • Alta Bates Comprehensive Cancer Center
    Berkeley, California 94704, United States
  • California Cancer Care
    Greenbrae, California 94904, United States
  • Tower Hematology Oncology Medical Group
    Los Angeles, California 90048, United States
  • Prostate Oncology Specialist/Pacific Clinical Research
    Marina Del Rey, California 90292, United States
  • UC Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
  • Southern California Permanente Medical Group
    San Diego, California 92120, United States
  • Sharp Healthcare
    San Diego, California 92121, United States
  • Pacific Hematology Oncology Associates
    San Francisco, California 94115, United States
  • Kaiser- Northern California
    Vallejo, California 94589, United States
  • San Diego Cancer Center
    Vista, California 92083, United States
  • Oncology Hematology Associates, Paudre Calley Cancer Ctr.
    Fort Collins, Colorado 80528, United States
  • University of Miami-Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Oncology Hematology Consultants
    Sarasota, Florida 34239, United States
  • Georgia Urology, P.A.
    Atlanta, Georgia 30342, United States
  • Georgia Cancer Specialists
    Tucker, Georgia 30084, United States
  • Loyola University Medical
    Maywood, Illinois 60153, United States
  • Midwest Cancer Research Group
    Skokie, Illinois 60077, United States
  • Urologic Associates- P.C.
    Davenport, Iowa 52807, United States
  • Oncology Hematology Care
    Crestview HIlls, Kentucky 41017, United States
  • Tulane University Hospital and Clinic
    New Orleans, Louisiana 70112, United States
  • Johns Hopkins University
    Baltimore, Maryland 21232, United States
  • Associates in Oncology Hematology P.C.
    Rockville, Maryland 20850, United States
  • Metro Minnesota CCOP
    St. Louis Park, Minnesota 55416, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • Univ. of Nebraska Medical Center/VA Hospital
    Omaha, Nebraska 68198, United States
  • New Mexico Cancer Care Associates
    Santa Fe, New Mexico 87505, United States
  • Lincoln Medical & Mental Health Center
    Bronx, New York 10459, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Columbia Presbyterian Medical Center
    New York, New York 10032, United States
  • Union State Bank Cancer Center
    Nyack, New York 10960, United States
  • Raleigh Hematology Oncology Clinic
    Cary, North Carolina 27511, United States
  • The Cleveland Clinic Foundation, Taussig Cancer Center
    Cleveland, Ohio 44195, United States
  • Mid Ohio Oncology Hematology, Inc.
    Columbus, Ohio 43222, United States
  • Oregon Health & Sciences University
    Portland, Oregon 97201, United States
  • NW Kaiser Permanente Portland
    Portland, Oregon 97227, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15232, United States
  • Charleston Hematology Oncology
    Charleston, South Carolina 29403, United States
  • Medical University of South Carolina - Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • University Oncology/ Hematology Associates
    Chattanooga, Tennessee 37403, United States
  • Boston Baskin Cancer Group
    Memphis, Tennessee 38104, United States
  • Professional Quality Research
    Austin, Texas 78756, United States
  • Texas Oncology, P.A.
    Dallas, Texas 75246, United States
  • Texas Cancer Care
    Fort Worth, Texas 76104, United States
  • Urology Associates of North Texas
    Ft. Worth, Texas 76104, United States
  • North Texas Regional Cancer Center
    Plano, Texas 75075, United States
  • Tyler Cancer Center
    Tyler, Texas 75702, United States
  • University of Washington Cancer Care
    Seattle, Washington 98109, United States
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • Vancouver Cancer Center
    Vancouver, British Columbia V5Z 4E6, Canada
  • CancerCare Manitoba
    Winnipeg, Manitoba R3E OV9, Canada
  • London Regional Cancer Centre
    London, Ontario N6A 4L6, Canada
  • Ottawa Regional Cancer Centre
    Ottawa, Ontario K1H 1C4, Canada
  • Toronto-Sunnybrook Regional Cancer Center
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Hospital, University Health Network
    Toronto, Ontario M5G 2M9, Canada
  • CHUM / Notre-Dame Hospital
    Montreal, Quebec H2L 4M1, Canada
  • Centre hospitalier universitaire de Quebec, Hotel-Dieu de Quebec
    Quebec, G1R 2J6, Canada
07

References and documents

Publications

  • Beer TM, Munar M, Henner WD. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer. 2001 Jun 15;91(12):2431-9. PubMed 11413535 ↗
  • Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol. 2003 Jan 1;21(1):123-8. doi: 10.1200/jco.2003.05.117. PubMed 12506180 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2002 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2002
First posted
Aug 13, 2002
Start
Aug 2002
Completion
Dec 2005
Last update
Mar 12, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Mar 12, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00043576
Lead sponsor
Novacea
First posted
Aug 13, 2002
Start date
Aug 2002
Completion
Dec 2005
Last update
Mar 12, 2009

Study contacts

Tomasz Beer, MD
study chair · Oregon Health and Science University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calcitriol · Docetaxel

Start the discussion